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Abstract
Background: Adult mammalian muscle retains incredible plasticity. Muscle growth and repair involves the activation of
undifferentiated myogenic precursors called satellite cells. In some circumstances, it has been proposed that existing
myofibers may also cleave and produce a pool of proliferative cells that can re-differentiate into new fibers. Such myofiber
dedifferentiation has been observed in the salamander blastema where it may occur in parallel with satellite cell activation.
Moreover, ectopic expression of the homeodomain transcription factor Msx1 in differentiated C2C12 myotubes has been
shown to induce their dedifferentiation. While it remains unclear whether dedifferentiation and redifferentiaton occurs
endogenously in mammalian muscle, there is considerable interest in induced dedifferentiation as a possible regenerative
tool.
Methodology/Principal Findings: We previously showed that the homeobox protein Barx2 promotes myoblast
differentiation. Here we report that ectopic expression of Barx2 in young immature myotubes derived from cell lines
and primary mouse myoblasts, caused cleavage of the syncytium and downregulation of differentiation markers.
Microinjection of Barx2 cDNA into immature myotubes derived from primary cells led to cleavage and formation of
mononucleated cells that were able to proliferate. However, injection of Barx2 cDNA into mature myotubes did not cause
cleavage. Barx2 expression in C2C12 myotubes increased the expression of cyclin D1, which may promote cell cycle re-entry.
We also observed differential muscle gene regulation by Barx2 at early and late stages of muscle differentiation which may
be due to differential recruitment of transcriptional activator or repressor complexes to muscle specific genes by Barx2.
Conclusions/Significance: We show that Barx2 regulates plasticity of immature myofibers and might act as a molecular
switch controlling cell differentiation and proliferation.
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Introduction
Adult mammalian muscle has the potential to regenerate by
activation of undifferentiated myogenic precursor cells (satellite
cells), which are normally quiescent and situated between the basal
membrane and the myofibers [1,2,3,4]. Upon activation, satellite
cells divide asymmetrically producing daughter cells with different
fates [5,6]. One daughter cell proceeds to proliferation and
myogenic differentiation and the other may return to the quiescent
satellite cell pool [7,8]. Urodele amphibians show much greater
regenerative plasticity than that of mammals, undergoing
epimorphic regeneration in which whole structures, rather than
isolated tissues are reformed [9,10]. This ability has been described
for many urodele organs, including lens, retina, intestine, tail and
limbs [11,12]. Previous experiments have shown that after
amphibian limb amputation, stump tissues form a structure called
the blastema in which cellular dedifferentiation occurs, producing
a pool of progenitor-like cells that participate in regeneration
[13,14]. For example, dedifferentiation of damaged amphibian
myofibers produces a pool of proliferating progenitor cells that can
re-differentiate to form new muscle.
It was previously suggested that dedifferentiated muscle cells
became multipotent and could contribute to development of not
only new muscle but also cartilage and bones [15]; however, more
recent work refutes this [16,17]. Although all cells in the newly
formed blastema have a very similar morphology, immunostaining
with tissue-specific markers has revealed heterogeneity of the
blastema cells [10,18]. In particular, a very recent study showed
that the blastema is a heterogeneous collection of progenitor cells
with restricted fates [16]. These experiments indicate that
dedifferentiating muscle remains restricted to the muscle lineage
[16]. Moreover, recent work suggests that the regeneration of
muscle during epimorphic limb regeneration involves not only
dedifferentiation of damaged myofibers, but also the activation of
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11612
muscle satellite cells as in mammals [12,19]. These data suggest
that amphibian and mammalian regeneration share more
similarity than was originally apparent.
Factors controlling dedifferentiation in newt limb are not well
understood; however, expression of the muscle segment homeobox
gene msx-1 is induced in the blastema [20] and also in regenerating
amputated mammalian digits [21], suggesting a role in dediffer-
entiation. This transcription factor is also expressed in migrating
limb muscle precursors preventing them from premature differ-
entiation [22,23,24]. While mammalian myofibers appear much
less plastic than those of the amphibian, it has been demonstrated
that ectopic expression of msx1 in mouse C2C12 myotubes induces
cleavage of myotubes into proliferating, mononucleated cells [25].
Moreover these cells appear able to re-differentiate into new
myofibers [25,26]. This suggests that the molecular and cellular
machinery that underpins functional dedifferentiation is present in
mammalian muscle. There is currently no convincing evidence
that dedifferentiation occurs naturally after injury of mammalian
muscle in vivo, and if it occurs it is unlikely to be a major
contributor to normal muscle regeneration. However, as recent
work on induced pluripotent stem cells (iPS cells) has shown, even
synthetic approaches to reprogramming differentiated cells can
have important ramifications for basic biology and lead to new
avenues in regenerative medicine [27,28]. Thus defining the
molecular mechanisms and factors involved in induced dediffer-
entiation in mammals may lead to development of new techniques
for control of cell and tissue plasticity.
In this study we investigated the role of the homeodomain
transcription factor Barx2 in regulation of myofiber plasticity.
During early embryonic stages of mouse development, Barx2 is
widely expressed in proliferating and differentiating cartilage and
muscle tissue [29]. However, in adult mice Barx2 expression was
found to be restricted to the joint region [29] and also to muscle
satellite cells [30]. We recently reported that Barx2 cooperates with
other muscle-expressed transcription factors to regulate cytoskel-
etal remodeling events of early myoblast differentiation [30].
Here we show that ectopic expression of Barx2 in C2C12
myotubes and MyoD-induced C3H10T1/2 myotubes induced
apparent dedifferentiation indicated by myotube cleavage and
concomitant down-regulation of muscle differentiation markers.
We also extended these studies to differentiated primary mouse
muscle cell cultures; we observed two types of myotubes in primary
cultures: thin slowly contracting myotubes with nuclei aligned
along the middle of the fiber (immature myotubes), and thicker,
faster contracting myotubes often with small or large nuclei
clusters (mature myotubes). Microinjection of Barx2 cDNA into
the immature myotubes induced cleavage and formation of
mononucleated cells that were able to proliferate, whereas
injection of Barx2 cDNA into mature myotubes induced myotube
contraction but not cleavage. Thus our data indicate that only
immature myotubes can dedifferentiate in response to Barx2 over-
expression, while more mature myotubes appear to have lost this
ability. These results also suggest that Barx2, like Msx1, can
regulate muscle plasticity and that homeobox factors could be a
part of a general mechanism that controls the susceptibility of cells
to reprogramming.
Results
We previously found that Barx2 is expressed in embryonic
myoblasts and satellite cells in vivo and is upregulated early during
differentiation of C2C12 and C3H10T1/2 cells and primary
myoblasts in culture. However, we do not observe Barx2 in the
nuclei of mature myofibres ([30,31] and unpublished data). To
examine the effects of ectopic Barx2 expression in differentiated
muscle cells, a Barx2 expression construct or control vector were
transfected into serum-deprived C2C12 cultures that were
comprised primarily of early-stage myotubes. Expression of GFP
demonstrates the high efficiency of transfection (Fig. 1A). Within
3–4 days, Barx2-expressing cultures showed a remarkable
reduction in myotube numbers due to apparent myotube
fragmentation (Fig. 1A). In contrast, control pcDNA3-transfected
cultures showed only maturing myotubes. Consistent with this
result, cultures ectopically expressing Barx2 showed decreased
levels of the differentiation-associated proteins myogenin and
myosin heavy chain (MyHC) (Fig.1B).
To further explore these phenomena, we performed similar
experiments with C3H10T1/2 mesenchymal progenitor cells that
were induced to undergo terminal differentiation and form
myotubes by transfection of MyoD and subsequent serum
withdrawal (Fig. 1C). As with C2C12 cells, coexpression of Barx2
and MyoD in these cells reduced myogenin (Fig. 1C) and MyHC
expression (Fig. 1C and 1D) and caused apparent cleavage of
myotubes with many shorter myotubes and mononucleated cells
present.
BrdU labeling showed the expected decrease in proliferating
cells in MyoD-transfected C3H10T1/2 cultures relative to
pcDNA3-transfected cells after several days in differentiation
media. This decrease was completely blocked by co-expression of
Barx2 (Fig.1E). This could indicate that Barx2 impairs differenti-
ation; however, our previous work has shown that Barx2 in fact
stimulates the earliest phases of differentiation in cooperation with
MyoD [30]. Thus we suggest that this result, together with our
observations of myotube fragmentation, further supports the idea
that Barx2 promotes dedifferentiation of terminally differentiated
myotubes. However, a clear caveat of the proliferation analysis is
that a subpopulation of mononucleated cells is always present in
the myotube cultures and proliferating cells may derive from these
cells rather than dedifferentiated myotubes. To specifically address
this concern we performed further experiments with a single-cell-
tracing technique and primary muscle cells as described below.
Satellite cells were isolated from postnatal day four mouse
skeletal muscle [30,32] and cultured as proliferating myoblasts.
Activation of primary myoblasts by serum withdrawal [30]
induced the expected rapid changes in cell shape, remodeling of
the actin cytoskeleton and expression of differentiation markers
(Fig. 2A). Specifically, within 1–3 hours after serum withdrawal,
myogenin expression was induced in activated myoblasts that were
undergoing cytoskeletal rearrangement as indicated by phalloidin
staining for F-actin [30] (Fig. 2A). We observed that myotube
formation/maturation in primary cultures happened in two
distinct stages. First long, thin, myotubes were formed. In these
myotubes nuclei were aligned toward the middle of the fiber (see
Fig. 2B) and the myotubes showed slow, infrequent contractions.
We considered these stage 1 or immature (young) fibers. These
immature myotubes appeared to be quite stable and did not show
any signs of spontaneous disassembly, such as we have observed in
forming myotubes by time-lapse microscopy [30]. Later the
majority of myotubes thickened and the nuclei moved along the
axis of the tube and often formed local aggregations either in the
middle or towards the end of the myotube (see Fig. 2C and D).
These more mature myotubes contracted more strongly and
frequently and appeared to represent the final stage (stage 2) of
primary myoblast differentiation. Our observations are presented
schematically in Figure 2E. Interestingly, even in very long-term
(two week) cultures, thin, slowly contracting myotubes without
nuclei clusters persisted in the culture. The existence of two similar
types of myotubes with and without nuclei clustering was
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described previously [33]. Moreover more myotubes with nuclei
clusters and larger nuclei aggregates were observed when
myotubes were co-cultured with neurons [33]. We also analyzed
Barx2 expression during primary myotube formation; specifically
Barx2 mRNA levels were measured by RT-PCR at different times
after activation of differentiation by serum withdrawal. Undiffer-
entiated proliferating primary myoblasts expressed Barx2 and its
expression was increased at least 3-fold by 6–9 hours after serum
withdrawal (Fig. 2F). Subsequently Barx2 expression levels were
reduced several fold below that of undifferentiated myoblasts
(Fig. 2F). This is consistent with our previous work [30,31]
indicating that Barx2 is important early in the myoblast
differentiation process and is subsequently downregulated in
mature myotubes. In particular, we previously found that ectopic
Barx2 expression in both undifferentiated C2C12 myoblasts and
primary cells increased proliferation and accelerated differentia-
tion [30], however it remained unclear why Barx2 expression is
strongly downregulated in myofibers.
To assess whether Barx2 can regulate plasticity of primary
myotubes, we isolated primary mouse myoblasts [32] and induced
their differentiation by serum withdrawal as described above. The
analysis of these cultures showed that even fully differentiated
cultures retain some undifferentiated mononucleated cells even
72–96 hours after induction of differentiation. As with the
experiments presented in Figures 1 and 2, this heterogeneity
could confound our results, i.e. newly proliferating cells might
derive from dedifferentiation of myotubes or from amplification of
existing mononucleated cells. To overcome this problem we
decided to perform experiments on single myotubes using
microinjection of plasmid DNA together with a cell tracing dye
(Fig. 3).
We performed injections of Barx2 cDNA or control plasmid
(empty pcDNA3 vector) into immature (stage 1) or mature (stage 2)
myotubes (Fig. 3A–E, and 3F–H respectively). Injections were
performed using a patch-clamp apparatus (see Materials and
Methods). To visualize and track injected myotubes, pcDNA3-
Barx2 or empty pcDNA3 (control) expression plasmids were
mixed with Alexa FluorH 488-conjugated dextran. To maximize
any proliferative response, both sets of injected myotubes were
subsequently stimulated with growth medium and medium was
replaced daily. Dedifferentiation was assessed by morphologic
examination of fluorescently labeled myotubes for signs of
cleavage, and by the appearance of myotube-derived (i.e.
fluorescently-labeled) mononucleated cells. Cleavage of young
myotubes was observed at day 4 after injection of the Barx2
plasmid yielding labeled, mononucleated cells (Figure 3A–D). An
example of a young injected multinucleated myotube that cleaved
to form five adjacent fluorescently labeled mononucleated cells is
shown in Figure 3B. Some of these fluorescently labeled
mononucleated cells derived from injected myofiber incorporated
Figure 1. Ectopic expression of Barx2 in differentiated myotubes causes their dedifferentiation. A. Serum-deprived C2C12 cultures
contaning many early myotubes were transfected with either Barx2/pcDNA, empty pcDNA3, or GFP-expressing plasmids. Images of maturing or
apparently fragmenting myotubes were taken after 3–4 days, B. Levels of the differentiation-associated proteins myogenin and myosin heavy chain
(MyHC) were measured by immunoblotting of total protein from Barx2-expressing and control cultures corresponding to those shown in A.
Untransfected myoblast and myotube cultures were also analysed as a reference. C. C3H10T1/2 mesenchymal progenitor cells were transfected with
either MyoD/pcDNA3 or a combination of MyoD/pcDNA3 and Barx2/pcDNA3 plasmids and differentiation was subsequently induced by serum
withdrawal for 2–3 days. The proportion of cells expressing myogenin and MyHC and appearance of myotubes was assessed by immunostaining. D.
MyHC protein was assessed by immunoblotting of total protein from cultures corresponding to those shown in C and D. Analysis of BrdU
incorporation was performed in C3H10T1/2 cultures corresponding to those shown in C; co-expression of Barx2 with MyoD increased numbers of
proliferating cells relative to MyoD alone - E.
doi:10.1371/journal.pone.0011612.g001
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BrdU (Fig. 3E). This finding suggests that the mononucleated cells
that arise from fragmentation of Barx2-injected myotubes are
viable and able to proliferate. Unfortunately the dye did not persist
long enough in the cells to assess whether they would be able to re-
differentiate if serum was withdrawn again.
In contrast to the results in immature myotubes, injections of
Barx2-plasmid into mature myotubes did not induce cleavage
(Fig. 3F–H); however, it did tend to induce contraction, nuclei
segregation and often myotube death. There was no sign of
myotube cleavage or contractions in either immature or mature
myotubes injected with empty plasmid DNA (not shown). Overall
these data indicate that Barx2 can promote dedifferentiation of
single immature myotubes.
Because our BrdU incorporation data suggested that Barx2 could
induce re-entry of myotube-derived cells into the cell cycle, we
examined whether Barx2 might affect cell cycle genes directly.
Quantitative RT-PCR analysis of C2C12 cells stably transfected
with a Barx2-expression plasmid showed that the cyclin D1 gene
was upregulated approximately 9-fold relative to control-transfected
cells (Fig. 4A). The D-type cyclins drive cells through the G0-G1-S
checkpoint, thus allowing quiescent cells to reenter the cell cycle
[34], which would be consistent with a role for reactivating
previously quiescent myonuclei after myotube dedifferentiation.
The data presented here combined with our previous work
[30,31] suggest that ectopic expression of Barx2 can have different
effects at different stages of myoblast differentiation. At an early
stage of myoblast differentiation, increased expression of Barx2
upregulates the expression of several myoblast differentiation
markers including a-smooth muscle actin (SMA) and accelerates
differentiation [30,31], while in myotubes, ectopic expression of
Figure 2. Differentiating myoblasts and maturating myotubes have different levels of Barx2 expression. A. Cultured primary myoblasts
were induced to differentiate by serum withdrawal and changes in cell shape, actin remodeling and myogenin expression were monitored over the
first 6 hours. B–D. Myotube maturation was examined between 24 and 72 hours post serum-withdrawal. At 24 hours myotubes were thin and
appeared immature (B). Between 48 and 72 hours, thicker myotubes appeared often with local aggregations of nuclei (C and D) and frequent strong
contractions. E. Observations of myotube maturation in culture presented schematically. F. Barx2 expression was measured by RT-PCR at different
stages of differentiation. Scale bars represent (A–C) - 20 mm, D–50 mm.
doi:10.1371/journal.pone.0011612.g002
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Barx2 appears to suppress the expression of differentiation-
associated genes (Fig. 1, 3). To further explore this notion of
differential gene regulation, we compared the regulation of a SMA
promoter-luciferase reporter construct by Barx2 in undifferentiat-
ed myoblasts or differentiated myotubes (Fig. 4B). Endogenous
SMA expression is known to be upregulated at an early stage of
myoblast differentiation, possibly to facilitate migration and
remodeling, and is subsequently downregulated and replaced by
skeletal muscle actin [35]. Moreover, we have previously shown
that Barx2 regulates the endogenous SMA gene and can directly
bind to the SMA promoter together with MyoD and increase
transcriptional activation of the promoter by MyoD in undiffer-
entiated myoblasts [30].
The regulation of the SMA promoter by Barx2 and MyoD was
examined by co-transfection of the SMA promoter-luciferase
construct with Barx2, MyoD, or empty pcDNA3 expression
plasmids in C2C12 cells (Fig. 4B). Consistent with our previous
studies [30], Barx2 increased activation of the SMA promoter by
MyoD in undifferentiated cell cultures. However, when promoter
activity was assayed after differentiation into myotubes, Barx2 was
found to moderately inhibit activation of the SMA promoter by
MyoD (Fig. 4B). This suggests that Barx2 may promote muscle
gene expression in myoblasts, yet repress the same and/or other
genes after differentiation.
We previously showed that Barx2 contains both an N-terminal
repression domain and a C-terminal activation domain [36] that
may recruit various co-repressors and co-activators respectively.
We also found that Barx2 interacts directly with positive regulators
of myogenesis including the bHLH factor MyoD, and its
coactivators including CREB-binding protein (CBP) [30]. Our
new observation that Barx2 can both up and downregulate the
SMA promoter depending on the state of cellular differentiation
prompted us to examine whether it may also interact with negative
bHLH regulatory factors.
The Hairy-enhancer of split (HES) family of bHLH factors act
as transcriptional repressors and have roles in maintaining
progenitor cells in an undifferentiated state and regulating cell
fate decisions during embryogenesis. For example, lack of certain
HES genes leads to premature differentiation in the nervous system
[37,38,39]. Hes6 has been previously shown to be an inhibitor of
myoblast differentiation in C2C12 myoblasts [40]. To assess
whether Barx2 and Hes6 can interact, co-immunoprecipitation
was performed after expression of both Barx2 and Hes6 proteins
in COS1 cells and C2C12 cells. We found that Barx2 can co-
immunoprecipitate Hes6 in both contexts (Fig. 4C). Taken
together with our previous work [30], we conclude that Barx2
can form complexes with both positive (i.e. MyoD) and negative
(i.e, Hes6) bHLH myogenic regulators. We also examined the
relative expression of Hes6 in C2C12 myoblasts and myotubes
using RT-PCR and found that Hes6 expression was relatively low
in undifferentiated C2C12 cells and was moderately upregulated
in both immature and mature myotubes (Fig. 4D). This result is
consistent with a previous non-quantitative analysis of Hes6
expression in C2C12 cells showing increased Hes6 mRNA after
induction of differentiation [40]. Our data prompt the hypothesis
that differential expression of factors such as Hes6, or other Barx2-
interacting repressors yet to be identified, could contribute to the
dual function of Barx2 at different stages of muscle development.
Discussion
The homeobox protein Barx2 is expressed during development of
skeletal and smooth muscle [41,42]. Barx2 is expressed in primary
myoblasts and its expression is upregulated soon after induction of
differentiation, while differentiated myotubes express virtually no
Barx2. This not only suggested a role for Barx2 early in myoblast
differentiation as previously investigated [30,31], but also that
subsequent repression of endogenous Barx2 in myofibres might be
Figure 3. Barx2 induces cleavage of mouse myotubes. A–D. Barx2/pcDNA3 or empty pcDNA3 plasmids were mixed with Alexa FluorH488-
conjugated dextran and then injected into immature (stage 1) myotubes. Cultures were stimulated with growth medium and fluorescently labeled
myotubes were monitored for signs of cleavage and appearance of labeled mononucleated cells. Scale bar represent 10 mm. E. BrdU labeling after
microinjection of myotubes. Single Alexa FluorH488-conjugated dextran-labeled cells occasionally incorporated BrdU suggesting they has re-entered
the cell cycle. Scale bar represent 10 mm. F–H. Mature (stage 2) myotubes were microinjected and examined as in A-D. No myotube cleavage was
observed. Scale bars represent F–10 mm, G - 50 mm, H–20 mm.
doi:10.1371/journal.pone.0011612.g003
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important for their function and/or integrity. Here we found that
ectopic expression of Barx2 in differentiated myotubes originating
from either cell lines or isolated muscle progenitors induced
myotube cleavage and downregulated differentiation markers. We
were also able to demonstrate increased cell proliferation after
ectopic Barx2 expression and using microinjection and cell tracing
show that proliferative cells arose from dedifferentiated myotubes.
These finding were similar to the previously described functions
of another homeodomain transcription factor - Msx1 [9,25].
Moreover, the regenerative plasticity of isolated urodele myofibers
is dependent on Msx1 [9] and Msx1 is involved in epimorphic digit
tip regeneration in both humans and mice [21,23]. It is possible
that Barx2 and Msx1 share similar pathways and even target genes
in the regulation of dedifferentiation. However, an important
difference between the functions of Barx2 and Msx1 is that Barx2 is
also able to promote the early stages of myoblast differentiation in
cooperation with MyoD [30]. This has not been reported for Msx1;
on the contrary expression of Msx1 in undifferentiated C2C12
myoblasts downregulates MyoD expression and inhibits differen-
tiation into myotubes [22,25,43]. Ectopic expression of Msx1 in
the forelimb and somites of chicken embryos also inhibits MyoD
expression and muscle differentiation [22].
Figure 4. Regulatory connections of Barx2 during muscle differentiation. A. Quantitative RT-PCR analysis of cyclin D1 expression in C2C12
cells stably transfected with a Barx2-expression plasmid or control plasmid. B. The SMA promoter-luciferase construct was co-transfected with
combinations of Barx2, MyoD, or empty pcDNA3 expression plasmids in C2C12 cells. Barx2 increased SMA promoter activation in undifferentiated cell
cultures yet inhibited activation in myotubes. C. Co-immunoprecipitation was performed after expression of both Barx2 and Hes6 proteins in COS1
cells and C2C12 cells. Barx2 co-immunoprecipitated Hes6 in both contexts. D. Expression of Hes6 was compared in C2C12 myoblasts and myotubes
using RT-PCR. Hes6 is upregulated in myotubes. E. Graphical representation of the RT PCR data shown in D (n – number of experiments).
doi:10.1371/journal.pone.0011612.g004
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It is interesting that in addition to Msx1 a number of homeobox
factors are capable of suppressing myogenic differentiation. These
include Mohawk which is a transcriptional repressor that blocks the
myogenic conversion of C3H10T1/2 cells [44]. The Pax3 and
Pax7 paired homeodomain transcription factors have also been
shown to suppress myogenic differentiation and both the paired
domain and homeodomain of Pax3 are required for this anti-
myogenic effect [45]. Thus, the Msx1, Mohawk, and Pax3/7
homeobox containing transcription factors appear to be general
repressors of myoblast differentiation. In contrast our previous and
current studies indicate that Barx2 positively regulates the early
steps of myoblast differentiation; however, its subsequent down-
regulation may be necessary for maintenance of the differentiated
state of myofibers.
The upregulation of cyclin D1 expression after overexpression
of Barx2 in C2C12 cells could be an important factor in promoting
cell cycle re-entry by myonuclei derived from dedifferentiated
myofibres. Re-entry into the cell cycle has been also induced in
terminally differentiated cultured cardiomyocytes by expression of
G1 cell cycle factors [46]. It is also of note that the highly
regenerative ‘scarless’ MRL mouse, which shares some properties
with newts and zebrafish in the formation of wound blastema and
apparent regeneration of heart muscle, was recently shown to lack
expression of p21 in regenerating tissue [47]. Moreover, p21 null
mice were recently shown to have a highly regenerative phenotype
similar to that of MRL mice. p21 is an inhibitor of cdk2, which is
involved in G1-S transition [48], supporting the idea that
modulation of genes that control cell cycle checkpoints might
alter the program of differentiated cells and allow increased
plasticity. Future work will examine how Barx2 regulates a
transcriptional program that allows cellular remodeling to be
coordinated with cell cycle re-entry.
Although mechanisms underlying differential gene regulation by
Barx2 at early and late stages of muscle differentiation are unclear,
they are very likely to involve differential recruitment of activator
or repressor complexes by Barx2 [36]. As we showed in previous
[30,36] and current studies, Barx2 can form complexes with both
positive and negative bHLH regulators of myogenesis; i.e. MyoD
and Hes6. The ratios between these complexes may thus be
important for determining Barx2 function at different stages of
myogenic differentiation.
Enforced expression of Hes6 has been found to inhibit
differentiation, leading to a higher proportion of thin, immature
myotubes relative to thickened, mature myotubes. Hes6 expression
also reduced the proportion of cells undergoing cell cycle
withdrawal and allowing more cells to re-enter the cell cycle after
differentiation [40]. These activities were independent of the DNA
binding domain of Hes6 and most likely depend on protein-
protein interactions [40]. Moreover, when injected into Xenopus
embryos, Hes6 increased the size of the myotome due to increased
proliferation; it also decreased markers of terminal muscle
differentiation [40]. While upregulated early in differentiation,
Hes6 is reported to be absent in mature myofibers in vivo, leading
to the suggestion that downregulation of Hes6 is required for
acquisition of a stable terminal differentiated state [40]. This
closely parallels the situation that we observe with Barx2.
Our corroborating finding of increased Hes6 expression in
C2C12 myotubes relative to myoblasts [40], together with the
interaction of Barx2 and Hes6, suggests that Hes6 may be one of
the repressors that interact with ectopic Barx2 in immature
myotubes and helps suppress muscle specific gene expression. This
interaction could contribute to suppression of myotube maturation
and allow immature myotubes to undergo dedifferentiation.
Consistent with the idea of functional cooperation between Barx2
and Hes6, previous work showed that the repression domain of
Barx2 binds directly to the transducin-like enhancer of split (TLE)
corepressor family [49]. TLEs are also essential corepressors for
Hes6 and other HES family repressors [49]. The role of Barx2-
Hes-TLE interactions in repression of gene expression is under
further investigation. Moreover, additional mechanisms for
repression of myogenic gene expression and reversal of the
differentiated state are also likely.
Homeodomain transcription factors regulate gene expression in
response to a large variety of extracellular stimuli, and act as
molecular switches for controlling cell differentiation, proliferation,
and apoptosis. Particular homeobox genes (Oct, Nanog) have been
shown to be important in induction of pluripotent stem cells (iPS
cells). Recent work comparing zebrafish regeneration blastema with
iPS cells showed that, although blastemal cells are not pluripotent,
some of the key iPS reprogramming factors including the Pou5
homeobox protein are also important for regeneration, presum-
ably due to their role in generating a multipotent cell state. This
suggests some common mechanisms may be involved in induced
cellular reprogramming and in the natural dedifferentiation
process observed in the blastema [50]. We now add Barx2 to the
list of homeobox regulators of adult cellular plasticity. In future
work it would be of considerable interest to assess the role of Barx2
in blastemal regeneration of muscle, perhaps in the zebrafish
context.
Materials and Methods
Cell cultures
Mouse C3H10T1/2 (clone 8) and C2C12 (ATCC) cells were
grown in Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) at 37C
in a humidified 5% CO2 atmosphere without antibiotics.
Preparation of primary myoblasts and immunostaining
Primary myoblast cultures were prepared as described previously
[32]. Cells were grown on collagen-coated plates or chamber slides
and maintained in growth medium (1:1 Ham’s F10/DMEM,
supplemented with 20% FBS and 2.5 ng/ml of basic FGF). Cells
were differentiated by transfer into differentiation medium (DMEM
supplemented with 2% horse serum). Cells were fixed with 2% of
paraformaldehyde at various time points after induction of
differentiation and processed for immunostaining. Antibodies to
myogenin (clone F5D; BD Bioscience Pharmingen), a-smooth
muscle actin (SMA) (clone 1A4; Sigma) or fast myosin heavy chain
(clone MF20 Developmental Studies Hybridoma Bank), were used
for immunostaining. Secondary antibodies (Molecular Probes,
Invitrogen) were conjugated to Alexa-488 or Texas Red. Rhoda-
mine-conjugated phalloidin was used to visualize F-actin.
Microscopy and image analysis
The Zeiss LSM 710 laser scanning confocal microscope
(LSCM) was used to obtain images. IMARIS software was used
for image analysis.
Cell transfections and promoter assays
16107 C2C12 cells were transfected with either 10 mg of
Barx2/pcDNA3 expression vector or pcDNA3 control plasmid
using Lipofectamine2000 reagent (Invitrogen). The Barx2 expres-
sion plasmid contains an in-frame NH2-terminal Myc tag and was
described previously [41]. In other experiments, an expression
plasmid bearing mCherry fluorescent protein linked to Barx2 via a
‘self-cleaving’ 2A peptide sequence was used to generate stable
lines by selection with puromycin in C2C12 cells. C3H10T1/2
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cells were co-transfected with MyoD and Barx2-pcDNA3 or with
MyoD and pcDNA3 plasmids. For analysis of smooth muscle actin
(SMA) promoter activity, a SMA promoter-luciferase construct
[30] was co-transfected with the Barx2-pcDNA3 expression vector
or pcDNA3 control plasmid and harvested either before or after
differentiation. The data shown were derived from at least three
independent experiments. Luciferase activity was analyzed as
previously described [30].
Western blotting
Total protein was prepared from C2C12 and C3H10T1/2 cells
using RIPA lysis buffer and sonicated. Equal aliquots of protein
were resolved by SDS-PAGE, transferred to polyvinylidene
difluoride membrane, and probed with antibodies to MyoD (clone
MoAb5.8A; BD PharMingen), skeletal fast myosin (clone MY-32;
Sigma), myogenin (clone F5D; BD Bioscience Pharmingen) and a
custom-made Barx2 anti-peptide polyclonal antibody (Covance). b-
actin, antibody was used as a reference. HRP conjugated secondary
antibodies and a chemiluminescent detection system was used to
visualize proteins. All experiments were performed in duplicates.
Co-Immunoprecipitation
Co-immunoprecipitation of Barx2 with Hes6 was performed as
essentially as described in [Zorn, 1999] Briefly, COS1 or C2C12
cells were co-transfected with the Barx2/pcDNA3 and Hes6/
pCMVSport6 (Open Biosystems) expression plasmids using
Lipofectamine-2000 (Invitrogen). Cell lysates were prepared
48 hours after transfection, pre-cleared with Protein A-Sepharose
and then incubated overnight at 4uC with 5 mg of anti-Barx2
rabbit antibody or preimmune serum. Complexes were precipi-
tated with Protein A-Sepharose, washed four times and resolved
by SDS-PAGE and immunoblotted with anti-Hes6 polyclonal goat
antibody (Santa Cruz Biotechnologies) antibody.
RNA isolation and RT PCR
RNA was isolated from undifferentiated C2C12 cells and
C2C12 young and mature myotubes using the RNeasy Plus Mini
Kit (Qiagen). The RNA was quantified using a Beckman DU 640
Spectrophotometer. 1 mg of each RNA sample was used to
synthesize cDNA using a First-Strand cDNA Synthesis kit and
SuperScript III/RNaseOUT Enzyme mix and 50 ng/ul random
hexamer primers. The RT PCR was performed using Perkin
Elmer 9600 PCR machine. Each sample was amplified with Hes6
primers: forward: ctcctgaaccacctgctagaatcc, reverse: ctaaggatgta-
gacaccaaatccggc, and GAPDH primers: forward: gtgaaggtcggtgt-
gaacggatttggccg; reverse: ccatggtggtgaagacaccagtagactcc. The
Hes6 primer set amplified a 252 base-pair DNA segment of the
Hes6 cDNA. The PCR products were resolved by agarose
electrophoresis, bands were quantified by densitometry, and the
ratio of Hes6/GAPDH PCR products was calculated. Three
experiments were performed, and the results were normalized
to the values from undifferentiated myoblast cultures. Statistical
(t-test) analysis was performed using Microsoft Exel.
Quantitative RT-PCR
RNA was prepared from primary myoblast or C2C12 cell
cultures using Trizol reagent (Gibco). Cells were lysed directly in
Trizol and RNA was prepared according to manufacturer protocol
(Invitrogen). RNA was treated with DNase using the DNA-free kit
(Ambion) and reverse transcribed using random primers and
MMluV reverse transcriptase (New England Biolabs). Quantitative
RT-PCR reactions were performed on an ABI 7300 machine using
Superarray Biosciences RT2 SYBR green reagent and the following
primers. Mouse Barx2 F: gtatttgtctaccccagacaggtt, R: tcatcctgc-
gattctgatacc; mouse Cyclin D1 F: tctttccagagtcatcaagtgtg, R:
gactccagaagggcttcaatc. Mouse GAPDH (NM_008084) (QIAGEN
SaBiosciences) and mouse ribosomal protein S26 (RPS26) F:
aggtgcagaaggctgagg, R: ggttctcccgagtgatgaag, were used as controls.
Intracellular injections
Injections into myofibers were performed using traditional patch-
clamp electrophysiology equipment [51]. Glass micropipettes (1 mm
outer diameter/0.58 internal diameter, WPI Inc., Sarasota, FL) were
pulled on a Sutter P97 Flaming/Brown puller (Sutter Instruments,
Novato, CA). Tips were approximately 1 mm in diameter, and had a
resistance in the bath of 2–5 MW.Micropipettes were backfilled with
internal patch solution containing (in mM) K-gluconate 110, KCl 10,
HEPES 10, Phosphocreatine 10, Mg-ATP 4, Na-GTP 0.3, Biocytin
0.1%, pH 7.3, with and osmolarity of 280–290 mOsm. The Barx2-
pcDNA3 and pcDNA (control) plasmids were mixed with fixable
Alexa FluorH 488-conjugated dextran; 10,000 kDa; (Invitrogen) and
added at a concentration of 0.5 mg/ml. Bath solution contained (in
mM) NaCl 124, KCl 3, NaPO4 1.25, NaHCO3 26, MgCl2 1,
Glucose 25, CaCl2 2.
BrdU labeling experiments
In experiments to assess the proliferation of cells derived from
microinjected myotubes, the cultures were maintained for an
additional 4–5 days and then incubated with 5-bromo-2-
deoxyuridine (BrdU) (Cell Proliferation Kit RPN20; Amersham
Biosciences) for one hour. Cultures were then fixed and BrdU
detection was performed using an Alexa FluorH 594-conjugated
secondary antibody according to the manufacturers protocol.
Proliferating BrdU-labeled cells were detected as fluorescein-
positive cells by confocal microscopy.
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